JPS6129930B2 - - Google Patents

Info

Publication number: JPS6129930B2
Authority: JP; Japan
Prior art keywords: oil; triacetin; mixed oil; antitumor agent; dissolved
Prior art date: 1983-09-21
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

JP17476083A

Other languages

English (en)

Japanese (ja)

Other versions

JPS6064917A (ja

Inventor

Taiji Okada

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

OKADA RAIFU KOOHOREISHON KK

Original Assignee

OKADA RAIFU KOOHOREISHON KK

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1983-09-21

Filing date

1983-09-21

Publication date

1986-07-10

1983-09-21 Application filed by OKADA RAIFU KOOHOREISHON KK filed Critical OKADA RAIFU KOOHOREISHON KK

1983-09-21 Priority to JP17476083A priority Critical patent/JPS6064917A/ja

1985-04-13 Publication of JPS6064917A publication Critical patent/JPS6064917A/ja

1986-07-10 Publication of JPS6129930B2 publication Critical patent/JPS6129930B2/ja

Status Granted legal-status Critical Current

Links

239000003921 oil Substances 0.000 claims description 60
URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 claims description 60
239000001087 glyceryl triacetate Substances 0.000 claims description 30
235000013773 glyceryl triacetate Nutrition 0.000 claims description 30
229960002622 triacetin Drugs 0.000 claims description 30
239000002246 antineoplastic agent Substances 0.000 claims description 23
238000010438 heat treatment Methods 0.000 claims description 19
239000008157 edible vegetable oil Substances 0.000 claims description 13
229960002949 fluorouracil Drugs 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 4
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 12
235000010445 lecithin Nutrition 0.000 description 12
229940067606 lecithin Drugs 0.000 description 12
239000000787 lecithin Substances 0.000 description 12
230000000694 effects Effects 0.000 description 10
238000001953 recrystallisation Methods 0.000 description 9
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 8
210000004881 tumor cell Anatomy 0.000 description 8
239000013078 crystal Substances 0.000 description 7
238000005481 NMR spectroscopy Methods 0.000 description 6
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
238000010521 absorption reaction Methods 0.000 description 6
230000007062 hydrolysis Effects 0.000 description 6
238000006460 hydrolysis reaction Methods 0.000 description 6
239000011261 inert gas Substances 0.000 description 5
239000000126 substance Substances 0.000 description 5
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
229910052805 deuterium Inorganic materials 0.000 description 4
238000000034 method Methods 0.000 description 4
239000000203 mixture Substances 0.000 description 4
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 4
229960004618 prednisone Drugs 0.000 description 4
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
230000001093 anti-cancer Effects 0.000 description 3
230000003647 oxidation Effects 0.000 description 3
238000007254 oxidation reaction Methods 0.000 description 3
239000000725 suspension Substances 0.000 description 3
IBSQPLPBRSHTTG-UHFFFAOYSA-N 1-chloro-2-methylbenzene Chemical compound CC1=CC=CC=C1Cl IBSQPLPBRSHTTG-UHFFFAOYSA-N 0.000 description 2
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
230000002411 adverse Effects 0.000 description 2
230000000259 anti-tumor effect Effects 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
238000000354 decomposition reaction Methods 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
150000004665 fatty acids Chemical class 0.000 description 2
239000007789 gas Substances 0.000 description 2
230000004727 humoral immunity Effects 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
238000003756 stirring Methods 0.000 description 2
WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 2
229960001674 tegafur Drugs 0.000 description 2
OVGDAVVFKDPXIC-UHFFFAOYSA-N 1-acetyl-5-fluoropyrimidine-2,4-dione Chemical compound CC(=O)N1C=C(F)C(=O)NC1=O OVGDAVVFKDPXIC-UHFFFAOYSA-N 0.000 description 1
QHLJWFQTGRWJRP-UHFFFAOYSA-N 6-acetyl-5-fluoro-1H-pyrimidine-2,4-dione Chemical compound CC(=O)c1[nH]c(=O)[nH]c(=O)c1F QHLJWFQTGRWJRP-UHFFFAOYSA-N 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
239000003470 adrenal cortex hormone Substances 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
238000009835 boiling Methods 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
238000001816 cooling Methods 0.000 description 1
235000013373 food additive Nutrition 0.000 description 1
239000002778 food additive Substances 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000011259 mixed solution Substances 0.000 description 1
150000004671 saturated fatty acids Chemical class 0.000 description 1
235000003441 saturated fatty acids Nutrition 0.000 description 1
238000005979 thermal decomposition reaction Methods 0.000 description 1
125000003944 tolyl group Chemical group 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Landscapes

Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

JP17476083A 1983-09-21 1983-09-21 抗腫瘍剤及びその製造法 Granted JPS6064917A (ja)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
JP17476083A JPS6064917A (ja)	1983-09-21	1983-09-21	抗腫瘍剤及びその製造法

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP17476083A JPS6064917A (ja)	1983-09-21	1983-09-21	抗腫瘍剤及びその製造法

Publications (2)

Publication Number	Publication Date
JPS6064917A JPS6064917A (ja)	1985-04-13
JPS6129930B2 true JPS6129930B2 (de)	1986-07-10

Family

ID=15984191

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP17476083A Granted JPS6064917A (ja)	1983-09-21	1983-09-21	抗腫瘍剤及びその製造法

Country Status (1)

Country	Link
JP (1)	JPS6064917A (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS61277622A (ja) *	1985-05-31	1986-12-08	Teijin Ltd	活性型ビタミンｄ３類製剤用組成物
NZ234802A (en) *	1989-08-14	1992-11-25	Merck & Co Inc	Long acting injectable formulations comprising an avermectin compound and triacetin. treatment for internal and external parasites of animals
JP6001845B2 (ja)	2011-11-30	2016-10-05	株式会社アマダホールディングス	製品保管方法，製品保管装置，加工システム，及び被保管製品の製造方法

1983
- 1983-09-21 JP JP17476083A patent/JPS6064917A/ja active Granted

Also Published As

Publication number	Publication date
JPS6064917A (ja)	1985-04-13

Publication	Publication Date	Title
Rose	1947	Synthesis of Cephalin1
EP0228612B1 (de)	1990-10-03	Alpha, alpha-Trehalose-Derivat und Verfahren zur Herstellung davon
JP2000511203A (ja)	2000-08-29	ピラジン化合物
DE2414680C2 (de)	1983-12-22	Substituierte 2-Furancarbonsäuren und 2-Furancarbonsäureester, Verfahren zu ihrer Herstellung und Arzneimittel, die diese Verbindungen enthalten
DE2845496A1 (de)	1979-04-26	N hoch 2 -substituierte phenyl-2,6- diaminonebularine und sie enthaltende arzneimittelzubereitungen
US2447715A (en)	1948-08-24	Esters of diacyl-glycerophosphoric acids
JPS6129930B2 (de)	1986-07-10
SU799662A3 (ru)	1981-01-23	Способ получени производныхбЕНзОилМОчЕВиНы
JPS5918399B2 (ja)	1984-04-26	有機ゲルマニウム重合体の製造方法
JP2909279B2 (ja)	1999-06-23	ホスファチジルコリン誘導体の製法
JPH08193050A (ja)	1996-07-30	９，１０− ジオキソアントラセン−２− カルボン酸誘導体及び該化合物を含む組成物
CH433378A (de)	1967-04-15	Verfahren zur Herstellung neuer Anthranilsäurederivate
CA1175856A (en)	1984-10-09	4-bis(phenylmethyl)amino)benzenesulfonic acids, virus inhibiting compositions containing them and method for inhibiting viruses
JPS61251694A (ja)	1986-11-08	新規フルクト−ス誘導体、その製法及びその用途
JPH0656840A (ja)	1994-03-01	デポー製剤
US4677110A (en)	1987-06-30	N-benzoyl-N'-pyrimidinyloxyphenyl urea compounds, and antitumorous compositions containing them
JPS6041670B2 (ja)	1985-09-18	２，６−ジメチル−１，４−ジヒドロピリジン−３，５−ジカルボン酸エステルおよびその製造方法
CN100352822C (zh)	2007-12-05	硫代磷酰胺类杀虫剂的衍生物
US3703544A (en)	1972-11-21	Process for preparing the tris(hydroxymethyl)-aminomethane salt of pge2
CN1012815B (zh)	1991-06-12	制备偕-二卤代-和四卤代-1，12-二氨基-4，9-二氮杂-十二烷的方法
JPS6036411A (ja)	1985-02-25	抗腫瘍剤及びその製造法
KR850000210B1 (ko)	1985-03-06	옥사졸린의 제조방법
JPS5857368A (ja)	1983-04-05	置換ピリミド−２−オン化合物
JPS6056981A (ja)	1985-04-02	１−（２−ヒドロキシエチル）−５−置換−１Ｈ−ピラゾロ〔３，４−ｂ〕ピラジン誘導体及び該化合物を含有する抗腫瘍剤
US4062975A (en)	1977-12-13	Amino substituted arylthio-alkanoic acids having hypolipidemic activity